Latest news
No-Moat UCB's Growth Products Fuel Revenue Expansion Amid Declining Sales for Legacy Drugs - MorningstarMorningstar · Fri, 31 Jul 2026 19:01:05 GMTSCLX Q1 2026 Earnings: Loss Per Share Widens Amid No Reported Revenue - Growth Acceleration Report - dars.gov.etdars.gov.et · Thu, 30 Jul 2026 23:40:47 GMTSPRO Q1 2026 Earnings: Positive EPS Surprise Amidst No Revenue Generation - Estimate Dispersion - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 23:42:30 GMTSCNI Q4 2023 Earnings: Better-than-Expected Losses Amid No Revenue - Dividend Growth Analysis - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMTBTCS Q1 2026 Earnings: Significant EPS Miss Amid No Revenue - Core Business Growth - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMTBTCS Q1 2026 Earnings: Significant EPS Miss Amid No Revenue - Surprise Factor Analysis - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMTSCLX Q1 2026 Earnings: EPS Widely Misses Amid No Revenue - Earnings Cycle Outlook - dars.gov.etdars.gov.et · Tue, 28 Jul 2026 07:00:00 GMT